Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients

Exclusion Criteria

• •Refusal to be included
• •Allergy or unsuitability to any composition of study drugs or remifentanil
• •Living expectancy less than 48 hours
• •Myasthenia gravis
• •Status asthmaticus
• •Abdominal compartment syndrome
• •Serious hepatic dysfunction (CTP 10-15);
• •Chronic kidney disease with glomerular filtration rate (GFR) \< 29 ml/min/1.73m2
• •Mean blood pressure less than 65 mm Hg or the need for a continuous infusion of norepinephrine at ≥0.5 ug/kg/min to maintain Mean blood pressure ≥ 65 mm Hg
• •Possible requirement for surgery or bedside tracheostomy in 24 hours
• •Possible requirement for renal replacement therapy in 24 hours
• •Acute severe neurological disorder and any other condition interfering with sedation assessment
• •Abuse of controlled substances or alcohol
• •Pregnancy or lactation